Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Verastem, Inc.
Providence Health & Services
Servier
Incyte Corporation
Wake Forest University Health Sciences
Shenzhen Hornetcorn Bio-technology Company, LTD
University of Alabama at Birmingham
University of Alabama at Birmingham
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Northwestern University
Eli Lilly and Company